Gene Editing Therapeutics Market Report 2024, Featuring Profiles of Key Players Allogene Therapeutics, CRISPR Therapeutics, Intellia Therapeutics, Sangamo Therapeutics and Vertex Pharmaceuticals - ResearchAndMarkets.com
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Shares May Have Slumped 29% But Getting In Cheap Is Still Unlikely
HC Wainwright & Co. Reiterates Buy on Sangamo Therapeutics, Maintains $5 Price Target
Sangamo Therapeutics Analyst Ratings
H.C. Wainwright Maintains Sangamo Therapeutics(SGMO.US) With Buy Rating, Maintains Target Price $5
H.C. Wainwright analyst Patrick Trucchio maintains $Sangamo Therapeutics(SGMO.US)$ with a buy rating, and maintains the target price at $5.According to TipRanks data, the analyst has a success rate
Earnings Update: Here's Why Analysts Just Lifted Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Price Target To US$3.80
Q2 2024 Sangamo Therapeutics Inc Earnings Call
Earnings Call: Sangamo Therapeutics Extends Cash Runway Into 2025
RBC Capital Remains a Hold on Sangamo Biosciences (SGMO)
Express News | Roche signed a $2 billion agreement to lay out Alzheimer's disease therapy.
Roche Strikes New Deal With Sangamo to Tackle Alzheimer's
Sangamo Therapeutics, Inc. (SGMO) Q2 2024 Earnings Call Transcript
Sangamo in Global Epigenetic Regulation and Capsid Delivery License Agreement With Genentech to Develop Novel Genomic Medicines for Neurodegenerative Diseases >SGMO
Sangamo Eligible to Earn Up to $1.9 B in Milestone Payments, Plus Tiered Royalties on Net Sales >SGMO
Sangamo Expects to Get $50 M in Near-Term Upfront License Fees and Milestone Payments >SGMO
Sangamo Therapeutics | 10-Q: Q2 2024 Earnings Report
Express News | Sangamo Therapeutics Q2 EPS USD -0.18 Vs. IBES Estimate USD -0.15
Express News | Sangamo Therapeutics Q2 Operating Income USD -37.084 Million
Express News | Sangamo Therapeutics Q2 Net Income USD -36.128 Million
Express News | Sangamo Therapeutics Q2 Adjusted Operating Expenses USD 31.9 Million